Did the FDA approve six new peptides? Not exactly. But one recent vote could have a major impact on where the industry goes from here.

In this episode of The Dr. Randi Show, Dr. Randi Boyette welcomes peptide expert Sarah Morgan back to the show to explain one of the biggest regulatory developments the peptide industry has seen in years. Together, they separate fact from fiction surrounding the FDA's recent Pharmacy Compounding Advisory Committee meeting, discuss what was actually recommended, and explain why this moment could help shape the future of peptides in aesthetics, wellness, and longevity.

They discuss:

FDA recommendation vs. FDA approval
What still must happen before access changes
The six peptides and what they're used for
The latest updates on retatrutide
What consumers should know about peptide sourcing
Where peptides fit into beauty, wellness, and longevity

From regulatory updates and peptide safety to future access, longevity medicine, and the growing connection between wellness and aesthetics, this episode explains why the FDA's latest actions have captured so much attention and what patients, providers, and the industry should be watching in the months ahead.

---

Listeners should not rely on any content from this podcast as a substitute for professional medical advice. Always consult a licensed physician or qualified healthcare provider regarding any medical concerns, treatments, or decisions. This podcast does not endorse or guarantee the safety or efficacy of any products, procedures, or services discussed.

This podcast is not intended for individuals under the age of 18.

Neither the host nor any guests assume liability for any loss, injury, or damage resulting from the use or application of the information discussed on this show.